AstraZeneca’s heart‑drug flop erases $27 B market value
AstraZeneca’s experimental heart‑drug Wainua missed its primary endpoint in a Phase III trial for transthyretin‑mediated amyloid cardiomyopathy, sending the stock down nearly 9% in London and 8% in U.S. pre‑market trading. The miss wipes about $27 billion off the company's market value and raises questions about its ability to expand Wainua beyond its existing indications.